Anagliptin

Drug profile

Key facts

Anagliptin is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2012. DrugCentral lists 4 molecular targets, including DPP4, DPP9 and DPP8. Recorded indications include Diabetes mellitus type 2.

• Molecular targets: DPP4, DPP9, DPP8 and FAP (4 listed in DrugCentral).
• Indications: Diabetes mellitus type 2.
• Molecular formula: C19H25N7O2; molecular weight 383.46 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetes mellitus type 2

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
Dipeptidyl peptidase 4	DPP4	inhibitor	IC50 8.42
Dipeptidyl peptidase 9	DPP9	unknown	IC50 7.22
Dipeptidyl peptidase 8	DPP8	unknown	IC50 7.17
Prolyl endopeptidase FAP	FAP	unknown	IC50 4.14

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2012-09-28	PMDA	—	—

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Anagliptin is on its molecule page.

• Molecular formula: C₁₉H₂₅N₇O₂
• Molecular weight: 383.46 g/mol
• CAS number: 739366-20-2
• InChIKey: LDXYBEHACFJIEL-HNNXBMFYSA-N
• PubChem CID: 44513473

CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Anagliptin used for?

DrugCentral lists the following indications for Anagliptin: Diabetes mellitus type 2.

How does Anagliptin work?

Its molecular targets in DrugCentral include DPP4 (inhibitor), DPP9, DPP8 and FAP.

When was Anagliptin first approved?

Anagliptin was first approved by the PMDA in 2012.

What is the chemical formula of Anagliptin?

Anagliptin has the molecular formula C19H25N7O2 and a molecular weight of 383.46 g/mol.

Sources

• DrugCentral drug card 4896 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1929387 — compound record and bioactivity
• PubChem CID 44513473 — chemical identifiers
• DrugBank DB12417 — drug record
• FDA UNII K726J96838 — substance identity
• UniProt P27487 (DPP4) — target protein
• UniProt Q86TI2 (DPP9) — target protein
• UniProt Q6V1X1 (DPP8) — target protein
• UniProt Q12884 (FAP) — target protein

How this page is built: methodology · editorial policy & corrections.